PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
August 23, 2025Indian Journal of Physiology and Pharmacology0 citations

Pharmacological assessment of Amaranthus viridis Linn against scopolamine-induced amnesia in experimental rat model

View Full Paper
KSK G SahanaSASyed Sagheer AhmedKCK. Chandan

Key Points

  • Amaranthus viridis significantly improves memory function in a scopolamine-induced amnesia rat model, enhancing cognitive abilities.
  • All doses of Amaranthus viridis extract (200, 400, and 800 mg/kg) showed a marked improvement in escape latency compared to the control group.
  • The assessment involved the Morris water maze and Novel object recognition tests to evaluate memory and cognitive performance.
  • Findings support Amaranthus viridis as a potential targeted therapy for neurodegenerative diseases like Alzheimer's.

Abstract

Objectives: Alzheimer’s disease (AD) is one of the many neurological conditions that impair memory and cognitive function and get worse with age. Amaranthus viridis Linn is a medicinal plant used as intervention for a wide varieties of ailment. A natural constituent omega 3 fatty acid present in A. viridis Linn possesses strong anti-inflammatory and antioxidant properties. Most of the drugs showed neuroprotective activity by inhibiting inflammation and oxidative stress in brain cells. Thus, we intended to evaluate pharmacological assessment of A. viridis Linn against scopolamine-induced amnesia in experimental rat model. Materials and Methods: The current study investigates whether A. viridis Linn can prevent scopolamine (SCP)-induced amnesia in female Wistar rats. The Morris water maze (MWM) and the Novel object recognition tests were used to assess memory-related behavioural factors. Every group except the control group received three oral doses of A. viridis extract (AVE) (200, 400 and 800 mg/kg) and daily intraperitoneal injections of scopolamine and donepezil at a dose of 1 mg/kg each for a total of 17 days. Results: When compared to the inducer group, all three doses showed shorter escape latency designating enhanced scopolamine-induced impairment. The long-term memory’s ability to recognise novel objects was also enriched by AVE, as shown by an improvement in the recognition index against chronic scopolamine-induced memory impairments. Acetylcholinesterase enzyme in particular brain areas (cortex, hippocampus) was dose-dependently inhibited by AVE. Conclusion: According to these research results, the AVE showed an improvement in memory function and may therefore represent a promising targeted therapy for neurodegenerative diseases.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sahana et al. (2025) studied this question.

synapsesocial.com/papers/68af59d2ad7bf08b1eade25dhttps://doi.org/10.25259/ijpp_355_2023
Ask AI
Helpful
Bookmark
Share
View Full Paper